Compacted hemostatic cellulosic aggregates

Patent metadata

Field	Value
Publication number	US-10034957-B2
Application number	US-201615337337-A
Country	US
Kind code	B2
Filing date	Oct 28, 2016
Priority date	Nov 6, 2015
Publication date	Jul 31, 2018
Grant date	Jul 31, 2018

Abstract

The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

First claim

I claim:

1. A method of making a plurality of hemostatic aggregates comprising the steps of:
a) milling a cellulosic source material to form fibers;
b) humidifying the fibers to water content of between 11.0% and 20% by weight;
c) roller compacting the fibers to form hemostatic aggregates;
d) sieving the hemostatic aggregates;
e) dehumidifying the hemostatic aggregates to a moisture content of less than 5.5% determined by loss on drying; and
f) optionally dosing the resulting hemostatic aggregates into storage containers or into delivery devices.

2. The method of claim 1 , wherein, the step a) is preceded by a step of slitting and cutting the cellulosic source material forming pieces acceptable for milling in step a).

3. The method of claim 2 , wherein, the step a) is a two-part process with the second part performed in an air classifier or ball mill process.

4. The method of claim 3 , wherein the second part is repeated three times.

5. The method of claim 4 , wherein the fibers have a size distribution of d50 less than about 100 microns and d90 of less than about 180 microns.

6. The method of claim 1 , wherein said step c) is performed by compacting the fibers into a compacted material which is then subjected to pre-breaking, followed by a step of final milling.

7. The method of claim 6 , wherein said compacting of the fibers is performed at a roller pressure of at least 125 bars.

8. The method of claim 6 , wherein said compacting the fibers is performed at a roller force of at least 26.0 kN/cm.

9. The method of claim 1 , wherein said step d) is performed to select a targeted hemostatic aggregates fraction having dimensions of 75-300 μm by screen sieving.

10. The method of claim 1 , wherein said step d) is performed to select a targeted hemostatic aggregates fraction characterized by a size distribution such that d15 greater than or equal to ≥80 microns, d50 is from 140 to 250 microns and d90 less than or equal to ≤370 microns.

11. The method of claim 1 , wherein said step e) is performed to hemostatic aggregates having moisture content of less than 2% determined by loss on drying.

12. The method of claim 1 wherein the source material is oxidized regenerated cellulosic fabric, oxidized regenerated cellulose non-woven fabric, shredded oxidized regenerated cellulosic material or combinations thereof.

13. The method of claim 1 wherein the source material further comprises an additive selected from the group consisting of carboxymethyl cellulose, calcium salt, an anti-infective agent, a hemostasis promoting agent, gelatin, collagen, of and combinations thereof.

14. The method of claim 1 further comprising a step of admixing an additive prior to step a), or prior to step b) by admixing the additive to the fibers; or prior to step c) by admixing the additive to the humidified fibers; or prior to step e) by admixing the additive to the hemostatic aggregates prior to drying or prior to step f) by admixing the additive to the hemostatic aggregates prior to dosing.

Assignees

• Ethicon Inc
• Ethicon Llc

Inventors

• Wang Yi-Lan

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61L15/24 Primary

  Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof {(A61L15/225 takes precedence)} · CPC title

• A61L26/0061

  Use of materials characterised by their function or physical properties · CPC title

• A61L26/0023 Primary

  Polysaccharides · CPC title